U.S. markets closed

Shareholders Are Raving About How The Ascendis Pharma (NASDAQ:ASND) Share Price Increased 554%

Simply Wall St

We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many investors. You won't get it right every time, but when you do, the returns can be truly splendid. For example, the Ascendis Pharma A/S (NASDAQ:ASND) share price is up a whopping 554% in the last three years, a handsome return for long term holders. Also pleasing for shareholders was the 32% gain in the last three months.

It really delights us to see such great share price performance for investors.

View our latest analysis for Ascendis Pharma

Because Ascendis Pharma made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

In the last 3 years Ascendis Pharma saw its revenue grow at 75% per year. That's well above most pre-profit companies. In light of this attractive revenue growth, it seems somewhat appropriate that the share price has been rocketing, boasting a gain of 87% per year, over the same period. It's always tempting to take profits after a share price gain like that, but high-growth companies like Ascendis Pharma can sometimes sustain strong growth for many years. So we'd recommend you take a closer look at this one, or even put it on your watchlist.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

NasdaqGS:ASND Income Statement, January 21st 2020

Ascendis Pharma is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

It's nice to see that Ascendis Pharma shareholders have gained 89% (in total) over the last year. That's better than the annualized TSR of 87% over the last three years. The improving returns to shareholders suggests the stock is becoming more popular with time. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 3 warning signs for Ascendis Pharma you should know about.

We will like Ascendis Pharma better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.